Key result
Volanesorsen decreases triglyceride levels in familial chylomicronemia syndrome but is associated with severe side effects including decreased platelet count and renal toxicity.
Why the study?
There are no FDA-approved medications to treat familial chylomicronemia syndrome, and volanesorsen is an emerging therapy for hypertriglyceridemia and familial chylomicronemia syndrome with differing regulatory approvals and notable side effects.
Answers are grounded in this paper and cite their sources.
Volanesorsen offers a novel mechanism for treating familial chylomicronemia syndrome, but its clinical utility is currently limited by severe side effects such as thrombocytopenia and renal toxicity.
Volanesorsen is a new medication that may soon be used in the treatment of hypertriglyceridemia and familial chylomicronemia syndrome (FCS). Volanesorsen works via binding to Apo C-III mRNA and degrading that mRNA, thus decreasing the synthesis of Apo C-III. This decreased synthesis of Apo C-III will increase the binding of triglycerides to LDL receptors and decrease triglyceride plasma levels. It is important to note that currently there are 3 other medication classes available for the treatment of hypertriglyceridemia, including niacin, fish oil/omega-3-fatty acids, and fibrates. However, there are no Food and Drug Administration-approved medications to treat FCS. Recently, volanesorsen was approved in the European Union for the treatment of FCS, but that indication was denied in the United States by the Food and Drug Administration. This was due to the side effects of the drug. Volanesorsen may cause a decrease in platelet count, renal toxicity, and elevate liver enzymes. The current drug regimen for volanesorsen consists of 285 mg once a week by subcutaneous injection, with a recommendation to immediately stop the medication if any of these side effects are noted, to prevent long-term complications. With these side effects reported, fish oil/omega-3-fatty acids seem likely the best choice when it comes to treating hypertriglyceridemia. If FCS is debilitating or greatly affecting the patient's life, then one could recommend volanesorsen. Otherwise, at this time, the side effects of volanesorsen may be too severe to justify its use for mild episodes of FCS or hypertriglyceridemia.
No takes yet. Share an insight, caveat, or question.
Gesner et al. (2022) conducted a review in Hypertriglyceridemia and familial chylomicronemia syndrome (FCS). Volanesorsen was evaluated. Volanesorsen decreases triglyceride levels in familial chylomicronemia syndrome but is associated with severe side effects including decreased platelet count and renal toxicity.
Synapse has enriched 10 related papers. Consider them for comparative context: